Characterization of a population evaluated for hepatocarcinoma in a third-level center.

IF 3.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-04-01 DOI:10.1016/j.aohep.2025.101796

Diana B. Lorenzo-Valle , Laura V. Cupil-Escobedo , Diego F. Abendaño-Rivera , Kenia M. Bastida-Guadarrama , Víctor M. Paez-Zayas , José L. Pérez-Hernández , María F. Higuera-de-la-Tijera

{"title":"Characterization of a population evaluated for hepatocarcinoma in a third-level center.","authors":"Diana B. Lorenzo-Valle , Laura V. Cupil-Escobedo , Diego F. Abendaño-Rivera , Kenia M. Bastida-Guadarrama , Víctor M. Paez-Zayas , José L. Pérez-Hernández , María F. Higuera-de-la-Tijera","doi":"10.1016/j.aohep.2025.101796","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Hepatocellular carcinoma is one of the most common cancers worldwide. Viral hepatitis, alcohol, and non-alcoholic fatty liver disease are important risk factors. To describe the clinical characteristics, staging, treatment, and outcomes of patients with HCC at a third-level hospital.</div></div><div><h3>Materials and Patients</h3><div>A retrospective, descriptive study was carried out from January 2021 to April 2024, in which 76 patients from the liver clinic consultation were included. Clinical characteristics, biochemical characteristics, staging and treatment were collected.</div></div><div><h3>Results</h3><div>The study included 76 patients, mean age 62 ±8(53.9% men); 88.1% of patients with cirrhosis; with the following etiologies: 30.2% due to MAFLD, 19.7% due to alcohol, 19.7% due to Hepatitis C and 18.4% due to other causes, With MELD 12 ±6.22, MELD Na 14.1± 5.4, 67 patients were classified in BCLC, of which 13.4% are in stage A, 59.7% B, 10.4% C, and 16.4% D. 36 patients were candidates for treatment distributing in 52.7% Transarterial Chemoembolization (TACE), 11.1% ablation, 11.1% TACE and ablation:; 2.7% Medical (Lenvatinib), 8.3% medical and radiological (Nivolumab/Lenvatinib with TACE/Ablation), 11.1% radiological (TACE) and transplant and 2.7% transplant. Treatment response evaluation according to mRESIST criteria: 11.1% complete response, 25% partial response, 33.3% stable disease and 27.7% progression. The 3-month mortality rate was 8.3%.</div></div><div><h3>Conclusions</h3><div>In our population group, mostly men, the most common etiology is MAFLD, two-thirds in intermediate stage, 47% were candidates for treatment, predominating the use of TACE. One-third remained with stable disease and 11.1% had a complete response. Mortality at 3 months was low.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101796"},"PeriodicalIF":3.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268125000201","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objectives

Hepatocellular carcinoma is one of the most common cancers worldwide. Viral hepatitis, alcohol, and non-alcoholic fatty liver disease are important risk factors. To describe the clinical characteristics, staging, treatment, and outcomes of patients with HCC at a third-level hospital.

Materials and Patients

A retrospective, descriptive study was carried out from January 2021 to April 2024, in which 76 patients from the liver clinic consultation were included. Clinical characteristics, biochemical characteristics, staging and treatment were collected.

Results

The study included 76 patients, mean age 62 ±8(53.9% men); 88.1% of patients with cirrhosis; with the following etiologies: 30.2% due to MAFLD, 19.7% due to alcohol, 19.7% due to Hepatitis C and 18.4% due to other causes, With MELD 12 ±6.22, MELD Na 14.1± 5.4, 67 patients were classified in BCLC, of which 13.4% are in stage A, 59.7% B, 10.4% C, and 16.4% D. 36 patients were candidates for treatment distributing in 52.7% Transarterial Chemoembolization (TACE), 11.1% ablation, 11.1% TACE and ablation:; 2.7% Medical (Lenvatinib), 8.3% medical and radiological (Nivolumab/Lenvatinib with TACE/Ablation), 11.1% radiological (TACE) and transplant and 2.7% transplant. Treatment response evaluation according to mRESIST criteria: 11.1% complete response, 25% partial response, 33.3% stable disease and 27.7% progression. The 3-month mortality rate was 8.3%.

Conclusions

In our population group, mostly men, the most common etiology is MAFLD, two-thirds in intermediate stage, 47% were candidates for treatment, predominating the use of TACE. One-third remained with stable disease and 11.1% had a complete response. Mortality at 3 months was low.

查看原文本刊更多论文

三级中心肝癌评估人群的特征。

肝细胞癌是世界范围内最常见的肿瘤之一。病毒性肝炎、酒精性和非酒精性脂肪肝是重要的危险因素。目的：描述三级医院HCC患者的临床特征、分期、治疗和预后。材料与患者回顾性描述性研究于2021年1月至2024年4月进行，纳入肝脏门诊会诊患者76例。收集患者的临床特征、生化特征、分期及治疗情况。结果共纳入76例患者，平均年龄62±8岁（男性53.9%）；肝硬化患者占88.1%；67例BCLC患者，MELD为12±6.22，MELD Na为14.1±5.4，其中A期为13.4%，B期为59.7%，C期为10.4%，d期为16.4%。36例患者为候选治疗对象，分布在52.7%的经动脉化疗栓塞（TACE）、11.1%的消融、11.1%的TACE +消融；2.7%医学（Lenvatinib）， 8.3%医学和放射学（Nivolumab/Lenvatinib + TACE/消融），11.1%放射学（TACE）和移植，2.7%移植。根据mRESIST标准评估治疗反应：11.1%完全缓解，25%部分缓解，33.3%病情稳定，27.7%进展。3个月死亡率为8.3%。结论在本组人群中，以男性为主，最常见的病因是MAFLD，三分之二为中期，47%为候选治疗，TACE的使用占主导地位。三分之一的患者病情稳定，11.1%的患者完全缓解。3个月死亡率低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.